Trusopt is a branded ophthalmic solution containing dorzolamide. It is used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The drug works by inhibiting the enzyme carbonic anhydrase in the ciliary body of the eye. This inhibition reduces the production of aqueous humor, the fluid that nourishes the front of the eye. With less fluid being generated, the pressure inside the eye decreases. The lowering of intraocular pressure helps to protect the optic nerve from damage caused by elevated pressure. Dorzolamide is a sulfonamide derivative that selectively blocks the activity of carbonic anhydrase isoforms present in ocular tissue. The systemic absorption of Trusopt is minimal, allowing its effects to remain localized to the eye.

Trusopt is an ophthalmic medication that contains the carbonic anhydrase inhibitor dorzolamide. It is used to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The drug works by blocking the enzyme carbonic anhydrase in the ciliary body of the eye. This inhibition reduces the production of aqueous humor, the fluid that nourishes the front of the eye. By decreasing aqueous humor volume the pressure inside the eye is lowered, which helps protect the optic nerve from damage. Trusopt is applied as a topical solution directly to the affected eye, allowing a high local concentration while limiting systemic exposure. Clinical studies have shown that it effectively reduces intraocular pressure by approximately fifteen to twenty percent when used as monotherapy or with other glaucoma agents. The pharmacologic effect is achieved through selective inhibition of carbonic anhydrase isoforms present in ocular tissue, leading to decreased bicarbonate formation and fluid secretion.

Trusopt may cause eye irritation or a burning sensation after use. Some users experience temporary blurred vision following administration. Headache or mild dizziness can occur in certain individuals. Rarely, an increased sensitivity to light may be reported. In some cases, conjunctival redness or mild swelling of the eyelid can develop. Systemic effects such as nausea are uncommon but have been documented.

Trusopt is a topical carbonic anhydrase inhibitor used to reduce intraocular pressure in patients with glaucoma. Common local side effects include transient eye irritation and a mild burning sensation upon application. Some users may experience temporary blurred vision immediately after dosing. A bitter or metallic taste can occur if the medication spreads to the oral cavity. Rarely systemic absorption may lead to hypersensitivity reactions such as rash or itching. In clinical studies a small proportion of patients reported headache or dry eyes as additional experiences. These effects are generally mild and often resolve with continued use.